08:00 , Nov 10, 2014 |  BC Week In Review  |  Company News

iBio, Novici Biotech deal

iBio and Novici expanded an exclusive commercialization deal focused on antibodies and vaccine products to include iBio's IBIO-CFB03. The endostatin-derived peptide is in preclinical development for idiopathic pulmonary fibrosis (IPF), systemic sclerosis and other...
07:00 , May 5, 2014 |  BC Week In Review  |  Company News

Oxford BioMedica, Sanofi deal

Oxford said Sanofi decided not to exercise the option the pharma received under an amended April 2009 deal for a worldwide license to develop and commercialize Oxford's RetinoStat to treat ocular diseases. Oxford BioMedica...
07:00 , Apr 14, 2014 |  BC Week In Review  |  Clinical News

RetinoStat: Completed Phase I enrollment

Oxford BioMedica completed enrollment of 21 patients in an open-label, dose-escalation, U.S. Phase I trial evaluating single subretinal injections of RetinoStat at 3 dose levels. Last June, the company suspended enrollment in the trials after...
08:00 , Feb 24, 2014 |  BC Week In Review  |  Company News

Oxford BioMedica, Sanofi deal

The companies amended an April 2009 deal to grant Sanofi broadened worldwide rights to StarGen and UshStat for all ocular disease indications in exchange for the return to Oxford of all worldwide rights...
08:00 , Feb 10, 2014 |  BC Week In Review  |  Company News

iBio, Medical University of South Carolina, University of Pittsburgh deal

The University of Pittsburgh granted iBio an exclusive license to patents and IP for an endostatin-derived peptide for idiopathic pulmonary fibrosis (IPF) and systemic sclerosis. iBio then partnered with Medical University of South Carolina (MUSC)...
07:00 , Oct 28, 2013 |  BC Week In Review  |  Clinical News

StarGen: Phase I/IIa ongoing

Oxford BioMedica said FDA and France's National Agency for the Safety of Medicine and Health Products (ANSM) agreed to allow the company to resume enrollment in Phase I/IIa trials of StarGen and UshStat and...
07:00 , Oct 28, 2013 |  BC Week In Review  |  Clinical News

UshStat: Phase I/IIa ongoing

Oxford BioMedica said FDA and France's National Agency for the Safety of Medicine and Health Products (ANSM) agreed to allow the company to resume enrollment in Phase I/IIa trials of StarGen and UshStat and...
07:00 , Oct 28, 2013 |  BC Week In Review  |  Clinical News

RetinoStat: Phase I ongoing

Oxford BioMedica said FDA and France's National Agency for the Safety of Medicine and Health Products (ANSM) agreed to allow the company to resume enrollment in Phase I/IIa trials of StarGen and UshStat...
07:00 , Sep 2, 2013 |  BC Week In Review  |  Company News

Simcere deal

Simcere said it is going private in a deal in which Chairman Jinsheng Ren and Assure Ahead Investments Ltd. will acquire all of the Simcere shares they do not already own for $4.83 per share...
07:00 , Sep 2, 2013 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Allenex AB (SSE:ALNX) gained SEK1.03 (48%) to SEK3.19 on Thursday after saying Mexico approved XM-ONE to detect human leukocyte antigen (HLA) and non-HLA antibodies between donor and recipient in organ transplantations. XM-ONE is an endothelial...